ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,042.34
      -0.42%
      US Tech 100
      20,879.60
      0.03%
      Dow Jones
      44,782.16
      -0.15%
      Brent Oil
      75.765
      -1.10%
      Bitcoin
      104,180.46
      2.81%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Astria Therapeutics Inc (ATXS) Quote

      Astria Therapeutics Inc

      Astria Therapeutics Inc (ATXS)

      NASDAQ
      7.50
      0.01
      ( 0.13% )
      Updated: 15:35:02
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      7.50
      Bid
      7.50
      Ask
      7.51
      Volume
      137,717
      7.40 Day's Range 7.63
      7.16 52 Week Range 16.90
      Market Cap
      423.257M
      Previous Close
      7.49
      Open
      7.49
      Last Trade
      8
      @
      7.49
      Last Trade Time
      15:35:16
      Financial Volume
      $ 1,035,702
      VWAP
      7.5205
      Average Volume (3m)
      327,690
      Shares Outstanding
      56,434,219
      Dividend Yield
      -
      PE Ratio
      -6.61
      Earnings Per Share (EPS)
      -1.29
      Revenue
      -
      Net Profit
      -72.89M

      About Astria Therapeutics Inc

      Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for... Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.astriatx.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Astria Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ATXS. The last closing price for Astria Therapeutics was $7.49. Over the last year, Astria Therapeutics shares have traded in a share price range of $ 7.16 to $ 16.90.

      Astria Therapeutics currently has 56,434,219 shares outstanding. The market capitalization of Astria Therapeutics is $422.69 million. Astria Therapeutics has a price to earnings ratio (PE ratio) of -6.61.

      Ask ADVFN Intelligence (AI)

      ATXS Latest News

      More News

      Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

      -- Early Proof-of-Concept Results from the Phase 1a Trial Anticipated in Q3 2025 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing...

      January 23 2025
      Business Wire

      Form 8-K - Current report

      January 13 2025
      Edgar (US Regulatory)

      Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

      -- Single Pivotal Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period -- -- Pioneering Patient-Centric Dosing Flexibility...

      January 13 2025
      Business Wire

      Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

      January 07 2025
      Edgar (US Regulatory)

      Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 58,650...

      January 03 2025
      Business Wire

      Form 8-K - Current report

      December 19 2024
      Edgar (US Regulatory)

      Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

      -- Navenibart Demonstrated 6 Months of HAE Attack Prevention with 1 or 2 Doses -- -- 90-95% Mean Monthly Attack Rate Reduction Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 67...

      December 11 2024
      Business Wire

      Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 32,500...

      December 03 2024
      Business Wire

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      November 14 2024
      Edgar (US Regulatory)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      November 14 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.04-0.530503978787.547.727.32787847.47607016CS
      4-1.46-16.29464285718.969.187.163084637.785119CS
      12-4.9-39.516129032312.412.477.163276909.31460389CS
      26-5.15-40.711462450612.6512.927.1632207310.48240811CS
      52-3.3-30.555555555610.816.97.1655405511.73983864CS
      1563.5891.32653061223.9216.92.3632420510.43228229CS
      260-1.03-12.07502930838.5316.92.3629314610.35508116CS

      ATXS - Frequently Asked Questions (FAQ)

      What is the current Astria Therapeutics share price?
      The current share price of Astria Therapeutics is $ 7.50
      How many Astria Therapeutics shares are in issue?
      Astria Therapeutics has 56,434,219 shares in issue
      What is the market cap of Astria Therapeutics?
      The market capitalisation of Astria Therapeutics is USD 422.69M
      What is the 1 year trading range for Astria Therapeutics share price?
      Astria Therapeutics has traded in the range of $ 7.16 to $ 16.90 during the past year
      What is the PE ratio of Astria Therapeutics?
      The price to earnings ratio of Astria Therapeutics is -6.61
      What is the reporting currency for Astria Therapeutics?
      Astria Therapeutics reports financial results in USD
      What is the latest annual profit for Astria Therapeutics?
      The latest annual profit of Astria Therapeutics is USD -72.89M
      What is the registered address of Astria Therapeutics?
      The registered address for Astria Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
      What is the Astria Therapeutics website address?
      The website address for Astria Therapeutics is www.astriatx.com
      Which industry sector does Astria Therapeutics operate in?
      Astria Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      DGNXDiginex Ltd
      $ 35.059
      (133.88%)
      		2.76M
      SLXNSilexion Therapeutics Corporation
      $ 3.0999
      (129.62%)
      		314.09M
      KRKR36Kr Holdings Inc
      $ 8.95
      (110.59%)
      		22.89M
      BNZIBanzai International Inc
      $ 1.8799
      (50.39%)
      		27.15M
      XFORX4 Pharmaceuticals Inc
      $ 0.722
      (49.85%)
      		24.86M
      ZKINZK International Group Co Ltd
      $ 0.497
      (-39.29%)
      		2.89M
      MGOLMGO Global Inc
      $ 0.1011
      (-39.21%)
      		50.86M
      EYENEyenovia Inc
      $ 0.03535
      (-37.98%)
      		22.71M
      BACKIMAC Holdings Inc
      $ 0.79
      (-35.25%)
      		2.14M
      BHATBlue Hat Interactive Entertainment Technology
      $ 0.0395
      (-31.66%)
      		87.98M
      NVDANVIDIA Corporation
      $ 122.89
      (-4.73%)
      		338.61M
      SLXNSilexion Therapeutics Corporation
      $ 3.0999
      (129.62%)
      		314.09M
      OCEAOcean Biomedical Inc
      $ 0.2506
      (-24.06%)
      		179.8M
      TNXPTonix Pharmaceuticals Holding Corporation
      $ 0.4366
      (-5.11%)
      		122.27M
      RIMEAlgorhythm Holdings Inc
      $ 0.0266
      (-13.92%)
      		120.31M

      ATXS Discussion

      View Posts
      Monksdream Monksdream 5 months ago
      ATXS under $15
      👍️0
      Monksdream Monksdream 7 months ago
      ATXS under $10
      👍️0
      Monksdream Monksdream 9 months ago
      ATXS under $10
      👍️0
      GreenStockEVs GreenStockEVs 2 years ago
      NEWS OUT - Astria Therapeutics Receives Fast Track Designation for STAR-0215 for the Treatment of Hereditary Angioedema

      About Astria Therapeutics:

      Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com.
      👍️0

      Your Recent History

      NASDAQ
      ATXS
      Astria Therapeutics
      AQEU
      MAIREM
      Maire
      AMEX
      DJE
      Tiers Djia 2003-1
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads